UBS Group
MYGN icon

UBS Group’s Myriad Genetics MYGN Stock Holding History

UBS Group’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-100
Closed -$1K – 8202
2020
Q1 		$1K Hold
100
– – ﹤0.01% 7780
2019
Q4 		$3K Buy
+100
New +$2.75K ﹤0.01% 7752
2015
Q1 		– Sell
-100
Closed -$3K – 9148
2014
Q4 		$3K Buy
+100
New +$3.55K ﹤0.01% 9249

Other funds holding MYGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group's MYGN Position: Q1 2026 in Review

UBS Group increased its Myriad Genetics (MYGN) stake by 9.9% in Q1 2026, buying an estimated $331K and bringing the position to 703,167 shares worth $3.16M. The position accounts for ﹤0.01% of the portfolio, ranked #4540.

UBS Group first reported a position in MYGN in Q4 2014 and has held it in 46 quarters since. The position peaked at $6.55M in Q4 2024. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • UBS Group held 703,167 shares of Myriad Genetics worth $3.16M as of Q1 2026.
  • UBS Group bought 63,476 Myriad Genetics shares in Q1 2026, an estimated $331K.
  • Myriad Genetics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4540 holding.
  • UBS Group first reported a position in Myriad Genetics in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Myriad Genetics position peaked at $6.55M in Q4 2024.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.